NantHealth announced the commercial availability of Genomic Proteomic Spectrometry Cancer, or GPS CancerT, a unique, comprehensive molecular test and decision support solution that measures the proteins present in the patient's tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor & normal samples.
GPS Cancer integrates targeted quantitative proteomics with whole genome (DNA) and whole transcriptome (RNA) sequencing, and a knowledge database containing hundreds of oncogenes and approximately 1,500 cellular pathways to identify genomic and proteomic alterations — from DNA to RNA to protein — targeting proteins with high clinical relevance to each person’s tumor and providing oncologists with a detailed molecular profile of a patient’s cancer to inform personalized treatment strategies.
With the capability to measure at a quantitative level, proteins which have known clinical significance relating to activity or resistance to chemotherapy, monoclonal antibody therapy (mAb), hormonal therapy, small molecule targeted therapy and checkpoint inhibitors, GPS CancerTM is the most comprehensive molecular profiling solution of a patient’s tumor tissue.
Combined with whole genome and transcriptomic analysis, this test provides informed clinical decision support, arming the physician with insight into the patient’s response and resistance to particular therapeutics before treatment begins. This valuable information is available within 21 days of receipt of the tissue, thus enabling clinical utility.
NantHealth will be exhibiting GPS CancerTM and its other solutions for cancer care at ASCO booth #12135 from June 3-June 7, 2016.
GPS CancerTM results are available to doctors in an easy-to-read report or accessible through the GPS CancerTM Genome Browser, a mobile application available on smartphones including the BlackBerry Priv.
The GPS Cancer Genome Browser is the first app enabling a physician and molecular scientists to browse the patient’s whole genome down to a single base pair and provide visual insight into genomic alterations coupled to relevant data about that alteration.
GPS CancerTM testing is conducted in the CLIA-certified and CAP-accredited laboratory of NantOmics, and is an enabler for the Cancer MoonShot 2020, the world’s most comprehensive cancer care collaborative seeking to accelerate the potential of combination immunotherapy as the next-generation standard of care in cancer patients.
"2016 has already been a banner year for NantHealth. On the heels of going public, today we’re announcing the commercial availability of GPS CancerTM as well as the launch of GPS Cancer Genome Browser at one of the most significant oncology events worldwide at ASCO. The ability to bring next-generation cancer treatments to patients marks a significant milestone in the war against cancer," said Dr. Patrick Soon-Shiong, Founder and CEO of NantHealth.
"While genomics has undoubtedly advanced our ability to treat cancer, gene panels have only given us a partial picture and only look at a fraction of the genome. We have leapfrogged from genomics to the era of clinically relevant proteomics with this comprehensive integration of DNA, RNA, and quantitative protein analysis in a single molecular test — GPS CancerTM.
Coupled with robust predictive analytics, this 21st century molecular profile offers clinicians and patients a powerful tool in fighting cancer at point of care and before treatment begins."
"Moreover, GPS CancerTM is an enabler for facilitating the goals of the Cancer MoonShot 2020, the nation’s most comprehensive cancer care initiative with the ambitious goal of creating a cancer vaccine by 2020, Dr Soon-Shiong added.
"GPS CancerTM may accelerate efforts to bring novel combinations of therapeutic agents to cancer patients by providing the molecular fingerprinting foundation necessary to help identify patients eligible for QUILT, Quantitative Integrative Lifelong Trials.
"These clinical trials, which are at the heart of Cancer MoonShot 2020, are aimed to accelerate the potential of immunotherapy as the new standard of care for cancer patients by harnessing the power of the immune system to fight this disease."
Today, many tests employ limited gene panels of 10-400 genes and a reference genome against which a patient’s tumor DNA is compared to identify alteration. GPS CancerTM sequences the whole genome of 20,000+ genes and 3 billion base pairs and matches against the patient’s normal DNA, providing oncologists with an expansive view of alterations to inform personalized treatment strategies specific for that patient.
GPS CancerTM extends from genomics to proteomics not only through analysis of RNA but also provides quantitative proteomics through mass spectrometry to measure the amounts of clinically relevant proteins that are the targets of or essential for various therapeutics.
This clinically relevant information helps oncologists to better understand how patients may potentially respond to chemotherapies, targeted therapies, and immunotherapies.
"GPS represents the new standard by which all complex molecular testing on tumors will be compared, there is no other CAP/CLIA approved genomic offering that come close to this level of sophistication and clinical utility." -Leonard Sender, MD, Medical Director of the Hyundai Cancer Institute at Children’s Hospital Orange County (CHOC Children’s).